Showing 15 posts of 95 posts found.


Regeneron shares two-year PULSAR trial results for wAMD

August 11, 2023
Medical Communications Opthalmology, PULSAR trial, Regeneron, wAMD

Regeneron Pharmaceuticals have announced positive, two-year, topline results from its PULSAR trial assessing aflibercept 8mg for the treatment of patients …

Regeneron’s drug cocktail shown to prevent symptomatic COVID-19

April 13, 2021
Manufacturing and Production COVID-19, REGEN-COV, Regeneron, covid-19 treatment, pharma, pharma news

Regeneron’s REGEN-COV treatment cocktail for COVID-19, a combination between casirivimab and imdevimab, has shown a significant reduction in progression to …


Phase III trial of Libtayo stopped early after positive overall survival results

March 15, 2021
Sales and Marketing Cancer, Libtayo, Regeneron, Sanofi

A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) will be stopped early after positive results demonstrated …


FDA approves Regeneron’s Evkeeza for HoFH

February 12, 2021
Medical Communications FDA, Regeneron

The FDA has approved Regeneron’s Evkeeza (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat …


Regeneron announces initial clinical data for COVID-19 antibody cocktail

December 18, 2020
Medical Communications COVID-19, Regeneron, antibody

Regeneron Pharmaceuticals has announced that initial clinical data published in the New England Journal of Medicine shows that its antibody …


Regeneron halts Phase 1 study into ultra-rare disease due to patient deaths

November 3, 2020
Manufacturing and Production, Research and Development Regeneron, clinical trials, garetosmab, pharma

Regeneron has slammed the brakes on its Phase 1 trial of garetosmab in the treatment of the ultra-rare condition fibrodysplasia …


Promising Phase 2 data for Sanofi and Regeneron’s PD-1 inhibitor Libtayo in locally advanced basal cell carcinoma

September 18, 2020
Medical Communications, Research and Development Cancer, ESMO 2020, Libtayo, Regeneron, Sanofi, pharma

Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi …


Regeneron seals $450m BARDA contract to scale up production of its COVID-19 vaccine

July 9, 2020
Manufacturing and Production, Sales and Marketing BARDA, Operation Warp Speed, Regeneron, US, vaccine COVID-19

Regeneron has revealed that REGN-COV2, its two-antibody vaccine for the treatment and prevention of COVID-19, has been awarded a manufacturing …


Sanofi and Regeneron’s Libtayo shows durable responses in world’s most common skin cancer

May 5, 2020
Manufacturing and Production, Research and Development Cancer, Libtayo, Regeneron, Sanofi

Sanofi and Regeneron’s have lifted the lid on new topline data on their PD-1 inhibitor Libtayo (cemiplimab) in patients with …


Phase 3 Libtayo monotherapy trial halted early due to strong benefit in advanced non-small cell lung cancer

April 29, 2020
Research and Development Cancer, Libtayo, Regeneron, Sanofi, lung cancer

A Phase 3 study of Sanofi and Regeneron’s Libtayo (cemiplimab) as a monotherapy for advanced or metastatic non-small cell lung …


NICE shoots down Dupixent for severe asthma

March 9, 2020
Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma

NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 …

Novartis’ Beovu approved in Europe after outclassing Eylea in wet age-related macular degeneration

February 18, 2020
Manufacturing and Production, Sales and Marketing Beovu, Eylea, Novartis, Regeneron, macular degeneration, pharma

The European Commission (EC) has chosen to approve Novartis’ Beovu (brolucizumab) injection, it has emerged, as a treatment for wet …


Sanofi and Regeneron’s Libtayo approved on NHS Scotland for cutaneous squamous cell carcinoma

February 11, 2020
Manufacturing and Production, Sales and Marketing Libtayo, NHS, Regeneron, Sanofi, Scotland, nhs scotland, pharma

Scottish patients will now be able to access Sanofi and Regeneron’s Libtayo (cemiplimab) via the NHS after it became known …


FDA approves Novartis’ Beovu injection for wet age-related macular degeneration

October 8, 2019
Manufacturing and Production, Sales and Marketing Beovu, Eylea, FDA, Novartis, Regeneron, pharma

Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it …


Regeneron invest $800 million into New York facilities

August 15, 2019
Medical Communications East Greenbush, New York, Regeneron, pharma

Regeneron is investing $800 million into its New York production facilities. The firm is planning to build a four story …

Latest content